跳至主要内容
临床试验/ISRCTN71342421
ISRCTN71342421已完成未知

The ‘DR-EAM’ study – (Type 2) Diabetes weight Reduction - Evaluation of App coaching Model

niversity of Westminster0 个研究点目标入组 250 人开始时间: 2021年6月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
250

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Minimum age of 18 years
  • 2. Maximum age of 65 years
  • 3. Male or female
  • 4. Minimum BMI of 27kg/m² (adjusted to 25kg/m² in people of South Asian or Chinese origin)
  • BMI <45kg/m²
  • 5. T2DM diagnosed at any time
  • 6. HbA1c eligibility, most recent value, which must be within 12 months:
  • 6.1. HbA1c = 43 mmol/mol if on oral diabetes medication or GLP-1
  • 6.2. HBA1c <108 mmol/mol - If HbA1c 90-108 mmol/mol, the value must be within 3 months of referral
  • 7. On, or about to start, a second-line diabetes-related oral medication or GLP-1 (metformin is first-line)
  • 8. Access to blood glucose monitoring equipment if on a sulphonylurea prior to referral
  • 9. Ability to speak, read and receive care in English
  • 10. Access to and willing to use an iOS or Android smartphone for the duration of the intervention

排除标准

  • 1. T2DM either diet-controlled alone, or on metformin alone
  • 2. Current insulin use
  • 3. Pregnant or breastfeeding or considering pregnancy during next 6 months
  • 4. Significant physical comorbidities:
  • 4.1. Active cancer
  • 4.2. Myocardial infarction or stroke within previous 6 months
  • 4.3. Severe heart failure defined as equivalent to the New York Heart Association grade 3 (NYHA)
  • 4.4. Recent eGFR <30 mls/min/1.73 m²
  • 4.5. Active live disease (except for NAFLD), or a history of hepatoma, or <6 months of onset of acute hepatitis
  • 4.6. Severe angina, cardiac arrhythmia including atrial fibrillation or prolonged QT syndrome
  • 5. Active substance use disorder/eating disorder
  • 6. Porphyria
  • 7. Weight loss >5% body weight within last 6 months or on current weight management programme or had/awaiting bariatric surgery (unless willing to come off waiting list)
  • 8. Health professional assessment that the person is unable to understand or meet the demands of the treatment programme and/or monitoring requirements, which may include Learning disabilities
  • 9. Taking monoamine-oxidase inhibitor medication
  • 10. Taking warfarin
  • 11. Taking varenicline (smoking cessation medication)
  • 12. Unstable retinopathy or lack of retinal screening in the last year
  • 13. Active/investigation for gastric or duodenal ulcers
  • 14. People currently participating in another clinical trial

研究者

发起方
niversity of Westminster

相似试验